POST Online Media Lite Edition



 

Novartis to answer U.S. Senate demand for data manipulation details

Christian Fernsby |
Novartis plans to answer a U.S. senator who demanded details about data manipulation related to its gene therapy Zolgensma, amid scrutiny of the Swiss drugmaker's decision to delay informing regulators until after the treatment's approval.<br><br>rn"We are planning to respond but we haven't submitted yet," a spokesman said on Monday.<br><br>rnU.S. Senate Finance Committee Chairman Chuck Grassley has asked the Basel-based company to give details on data manipulation on its $2.1 million gene therapy to treat spinal muscular atrophy by Aug. 23. <br><br>rnNovartis, which won appro

Article continues below



Topics: NOVARTIS    U.S.   

ttps://www.histerius.com/hs0819/novartis.jpg" class="slikadesno" alt="Novartis" title="Novartis">Novartis plans to answer a U.S. senator who demanded details about data manipulation related to its gene therapy Zolgensma, amid scrutiny of the Swiss drugmaker's decision to delay informing regulators until after the treatment's approval.

"We are planning to respond but we haven't submitted yet," a spokesman said on Monday.

U.S. Senate Finance Committee Chairman Chuck Grassley has asked the Basel-based company to give details on data manipulation on its $2.1 million gene therapy to treat spinal muscular atrophy by Aug. 23.

Novartis, which won approval for Zolgensma in May has terminated several scientists amid an internal investigation.


What to read next

Novartis loses India patent case on Glivec
U.S. sues 'repeat offender' Novartis
Novartis is buying ofatumumab from GSK for $1 billion